Modal

/ Rafa

Vertigo
Average dosage: The treatment is initiated with low dosages in adults, with 50-100mg per day, in divided doses.
As a rule, the maintenance dose for adults is 150-300 mg per day, in divided
doses.
Severe cases: The dosage may be increased. The duration of treatment should not be less than 15 days and should be continued for several weeks if necessary.
Psychiatry
Initial dose of 200-400 mg twice daily, increasing if necessary to a maximum of 1200 mg twice daily. Maintenance dose 600-800 mg per day in divided doses.
Psychiatry – Elderly: The same dose ranges may be required in the elderly, but, as a general rule with the use of psychotropics in elderly patients, starting doses should be lower and increased gradually, particularly in those with renal impairment.
Psychiatry – Children aged above 6 years old: 3-5 mg/kg body weight/day in devided doses.
Renal Failure: Sulpiride is primarily excreted renally, and dose adjustments have been suggested in renal insufficiency.
– creatinine clearance 30 to 60 mL/minute – 50% of normal dose
– creatinine clearance 10 to 30 mL/minute – 30% of normal dose
– creatinine clearance <10 mL/minute – 20% of normal dose.

Schizophrenic states with symptoms of apathy and apragmatism, acute confusional states, depressive states of various origins, including geriatric cases, neurosis with psychomotoric inhibitions, childhood and adolescence psychoses, prepsychotic states.

Acute agitation and mania, suspected or existing pheochromacytoma, Parkinsonism. Consumption of high doses of CNS depressant drugs, alcoholism, comatose states, severe CNS depression, known sensitivity to the drug. Pregnancy and lactation.

High blood pressure, severe cardiac diseases, renal and liver impairment, ataxia, epilepsy, glaucoma, prostatic hypertrophy and blood discrasias. Caution is required for any kind of surgery, dental treatment or emergency treatment because of possible drug interactions or blood dyscrasias. Possible heat stroke, possible hypothermia, ocular changes.

Dyskinesia and extrapyramidal syndromes may occur, unexplained hyperthermia, sedation or somnolence, dry mouth, blurred vision, ocular changes, pigmentary retinopathy.

May potentiate the action of hypotensive and antihypertensive drugs, antidepressants and CNS depressants, hypnotics, tranquilizers, anesthetics and anelgesics.